{"nctId":"NCT02163447","briefTitle":"Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants","startDateStruct":{"date":"2014-06-23","type":"ACTUAL"},"conditions":["Malaria"],"count":300,"armGroups":[{"label":"3 dose SP pregnancy / 3 monthly DP infancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy","Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants"]},{"label":"3 dose DP pregnancy / 3 monthly DP infancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy","Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants"]},{"label":"3 dose DP pregnancy / monthly DP infancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy","Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants"]},{"label":"monthly DP pregnancy / 3 monthly DP infancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy","Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants"]},{"label":"monthly DP pregnancy / monthly DP infancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy","Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants"]}],"interventions":[{"name":"Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy","otherNames":["Duo-Cotexin (Holley-Cotec)"]},{"name":"3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy","otherNames":["Duo-Cotexin (Holley-Cotec)"]},{"name":"3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy","otherNames":["Kamsidar (KPI)"]},{"name":"Monthly dihydroartemisinin-piperaquine (DP) for infants","otherNames":["Duo-Cotexin (Holley-Cotec)"]},{"name":"3-monthly dihydroartemisinin-piperaquine (DP) for infants","otherNames":["Duo-Cotexin (Holley-Cotec)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound\n2. Estimated gestational age between 12-20 weeks\n3. Confirmed to be HIV uninfected by rapid test\n4. 16 years of age or older\n5. Residency within 30km of the study clinic\n6. Provision of informed consent by the pregnant woman for herself and her unborn child\n7. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol\n8. Plan to deliver in the hospital\n\nExclusion Criteria:\n\n1. History of serious adverse event to SP or DP\n2. Active medical problem requiring inpatient evaluation at the time of screening\n3. Intention of moving more than 30km from the study clinic\n4. Chronic medical condition requiring frequent medical attention\n5. Prior SP preventive therapy or any other antimalarial therapy during this pregnancy\n6. Early or active labor (documented by cervical change with uterine contractions)","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Prevalence of Placental Malaria","description":"Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Malaria in Pregnant Women","description":"Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"0.31","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Malaria in Infants","description":"Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.30","spread":null},{"groupId":"OG002","value":"0.00","spread":null},{"groupId":"OG003","value":"0.43","spread":null},{"groupId":"OG004","value":"0.03","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Malaria in Infants","description":"Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null},{"groupId":"OG001","value":"0.88","spread":null},{"groupId":"OG002","value":"0.83","spread":null},{"groupId":"OG003","value":"1.24","spread":null},{"groupId":"OG004","value":"0.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP","description":"Prevalence of placental blood samples positive for parasites by microscopy or LAMP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery","description":"Prevalence of maternal parasitemia at delivery by microscopy and LAMP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery","description":"Congenital malformations, spontaneous abortion, LBW (\\<2500g), still birth, pre-term delivery","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Anemia in Pregnant Women","description":"Prevalence of routine hemoglobin measurements \\< 11 g/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Complicated Malaria in Infants","description":"Any treatment for malaria meeting criteria for severe malaria or danger signs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":null},{"groupId":"OG001","value":"0.024","spread":null},{"groupId":"OG002","value":"0.000","spread":null},{"groupId":"OG003","value":"0.035","spread":null},{"groupId":"OG004","value":"0.000","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hospital Admissions in Infants","description":"Admission to a hospital for pediatric inpatient care for any reason","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":null},{"groupId":"OG001","value":"0.036","spread":null},{"groupId":"OG002","value":"0.089","spread":null},{"groupId":"OG003","value":"0.082","spread":null},{"groupId":"OG004","value":"0.043","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Gametocytemia in Pregnant Women","description":"Proportion of urgent blood smears positive for gametocytes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Parasitemia in Infants","description":"Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy","description":"Detection of malaria parasites by LAMP during pregnancy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Gametocytemia in Infants","description":"Proportion of routine blood smears positive for gametocytes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":106},"commonTop":["Cough","Diarrhea","Abdominal pain","Vomiting","Headache"]}}}